ID
22302
Description
Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Subject Status / Response Assessment, 6 Month Post-Therapy Follow-up Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast
Link
https://clinicaltrials.gov/ct2/show/NCT00078572
Keywords
Versions (1)
- 5/29/17 5/29/17 -
Uploaded on
May 29, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
XELODA and Lapatinib Advanced or Metastatic Breast Cancer 6 Month Post-Therapy Follow-up NCT00078572
XELODA and Lapatinib Advanced or Metastatic Breast Cancer 6 Month Post-Therapy Follow-up NCT00078572
Description
Response Assessment
Alias
- UMLS CUI-1
- C0521982
- UMLS CUI-2
- C0220825
- UMLS CUI-3
- C0678222
Description
If NO, complete the rest of this page.
Data type
text
Alias
- UMLS CUI [1]
- C0242656
Description
lesion
Data type
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0221198
- UMLS CUI [1,3]
- C0220825
Description
Response assessment
Data type
text
Alias
- UMLS CUI [1]
- C0521982
Description
method
Data type
text
Alias
- UMLS CUI [1,1]
- C0871511
- UMLS CUI [1,2]
- C0221198
- UMLS CUI [1,3]
- C0220825
Description
If Symptomatic progression of cancer is checked, complete details below
Data type
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0178874
Description
Specify symptoms
Data type
text
Alias
- UMLS CUI [1,1]
- C1457887
- UMLS CUI [1,2]
- C0178874
Similar models
XELODA and Lapatinib Advanced or Metastatic Breast Cancer 6 Month Post-Therapy Follow-up NCT00078572
C1522577 (UMLS CUI-2)
C0678222 (UMLS CUI-3)
C0920425 (UMLS CUI [1,2])
C0220825 (UMLS CUI-2)
C0678222 (UMLS CUI-3)
C0221198 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,3])
C0221198 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,3])
C0178874 (UMLS CUI [1,2])
C0178874 (UMLS CUI [1,2])